Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Collegium PharmaceuticalCOLL -0.10%70 3-Year EBITDA Growth Rate is 25.40% as of Jun. 2026, which is at its 10-year median of 25.40. GuruFocus rates COLL with a GF Scoreâ„¢ of 70/100 and a GF Valueâ„¢ of $46.82 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 809 Drug Manufacturers companies, Collegium Pharmaceutical ranks better than 74.78% on this metric.
During the past 12 months, Collegium Pharmaceutical's average EBITDA Per Share Growth Rate was 10.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 25.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 33.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Collegium Pharmaceutical was 63.40% per year. The lowest was -21.70% per year. And the median was 25.40% per year.
Collegium Pharmaceutical (NAS:COLL) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Collegium Pharmaceutical 3-Year EBITDA Growth Rate Related Terms
COLL vs ETON, ALVO, PCRX: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's 3-Year EBITDA Growth Rate falls into.
Collegium Pharmaceutical 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 25.40% mean?
Collegium Pharmaceutical (COLL) has a 3-Year EBITDA Growth Rate of 25.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Collegium Pharmaceutical and its competitors. This is near median its historical median of 25.40. According to the industry distribution chart, Collegium Pharmaceutical ranks #204 out of 809 companies in the Drug Manufacturers industry, placing it in the top 25.2%.
Is Collegium Pharmaceutical's 3-Year EBITDA Growth Rate too high?
Collegium Pharmaceutical's current 3-Year EBITDA Growth Rate of 25.40% is near median its 10-year median of 25.40. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Collegium Pharmaceutical's value of 25.40% is 185.4% above this industry median. Based on the distribution chart, Collegium Pharmaceutical ranks #204 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Collegium Pharmaceutical has a GF Scoreâ„¢ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's 3-Year EBITDA Growth Rate compare to ETON and ALVO?
According to the Drug Manufacturers industry distribution chart, Collegium Pharmaceutical ranks #204 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Collegium Pharmaceutical in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Collegium Pharmaceutical's value of 25.40% is 185.4% above this benchmark. While the company's 10-year median is 25.40 vs. the industry median of 8.90, Collegium Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Collegium Pharmaceutical's current 3-Year EBITDA Growth Rate of 25.40% is 185.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Collegium Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Collegium Pharmaceutical's current 3-Year EBITDA Growth Rate is 25.40%, which is near median its own 10-year median of 25.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (COLL) is currently considered Possible Value Trap. The stock's GF Value™ is $46.82, compared to a current price of $28.74 — trading 38.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 25.40%, which is near median its 10-year median of 25.40 and 185.4% above the Drug Manufacturers industry median of 8.90. Collegium Pharmaceutical's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Collegium Pharmaceutical (COLL), the current 3-Year EBITDA Growth Rate is 25.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Collegium Pharmaceutical (COLL) Overvalued in 2026?
Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued.
The current stock price of $28.74 is trading 38.6% below its estimated GF Value™ of $46.82.
GuruFocus considers Collegium Pharmaceutical to be Possible Value Trap.
Key valuation signals for COLL:
3-Year EBITDA Growth Rate: 25.40% (near median its 10-year median of 25.40)
GF Value™: $46.82 vs. price of $28.74 (38.6% below fair value)
Industry Position: 185.4% above the Drug Manufacturers median (#204 of 809)
No single metric tells the full story. See the COLL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
70GF Score
Get the complete analysis for COLL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COLL has been successfully added to your 
